Sunshine Financial Statements From 2010 to 2024

SBFM Stock  USD 2.44  0.08  3.39%   
Sunshine Biopharma financial statements provide useful quarterly and yearly information to potential Sunshine Biopharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Sunshine Biopharma financial statements helps investors assess Sunshine Biopharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Sunshine Biopharma's valuation are summarized below:
Gross Profit
1.7 M
Profit Margin
(0.13)
Market Capitalization
4.7 M
Enterprise Value Revenue
39.4772
Revenue
33 M
There are over one hundred nineteen available fundamental trend indicators for Sunshine Biopharma, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to double-check Sunshine Biopharma's current fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road.

Sunshine Biopharma Total Revenue

25.3 Million

Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 30.3 M or Total Operating Expenses of 13.8 M, as well as many indicators such as Price To Sales Ratio of 0.26, Dividend Yield of 0.0 or PTB Ratio of 0.3. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.
  
Check out the analysis of Sunshine Biopharma Correlation against competitors.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.

Sunshine Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets28.7 M27.3 M6.1 M
Slightly volatile
Total Current Liabilities5.8 M5.6 M1.6 M
Slightly volatile
Accounts Payable2.7 M2.6 M577 K
Slightly volatile
Cash17.1 M16.3 M3.9 M
Slightly volatile
Cash And Short Term Investments17.1 M16.3 M3.9 M
Slightly volatile
Common Stock Shares Outstanding8.8 K12.2 K8.1 K
Slightly volatile
Liabilities And Stockholders Equity28.7 M27.3 M6.1 M
Slightly volatile
Non Current Liabilities Total480.3 K587.8 K523.7 K
Slightly volatile
Other Stockholder Equity88.6 M84.4 M25.8 M
Slightly volatile
Total Liabilities6.4 M6.1 M1.9 M
Slightly volatile
Total Current Assets26.1 M24.9 M5.5 M
Slightly volatile
Common Stock26.6 K28 K178.5 K
Very volatile
Short and Long Term Debt TotalM657.7 K951 K
Slightly volatile
Other Current Liabilities2.7 M2.5 M396.4 K
Slightly volatile
Other Assets97 K92.3 K76.9 K
Slightly volatile
Other Current Assets326.1 K310.6 K69.8 K
Slightly volatile
Short Term Debt112.7 K118.7 K730.9 K
Slightly volatile
Short and Long Term Debt4.4 M4.2 M1.4 M
Slightly volatile
Property Plant And Equipment Net1.1 MM243.4 K
Slightly volatile
Non Current Assets Total2.6 M2.5 M788.3 K
Slightly volatile
Net Receivables2.7 M2.6 M485.8 K
Slightly volatile
Property Plant Equipment7.7 K8.1 K14.6 K
Pretty Stable
Long Term Debt2.3 M2.2 M740.3 K
Slightly volatile
Other Liabilities36.8 K38.7 K190.4 K
Slightly volatile
Current Deferred Revenue192.1 K344.8 K145.4 K
Slightly volatile
Good Will532.6 K599.1 K652.4 K
Slightly volatile
Capital Stock27.6 K29 K129 K
Pretty Stable
Short Term Investments6.1 K6.8 K7.4 K
Slightly volatile
Property Plant And Equipment Gross1.3 M1.2 M297.2 K
Slightly volatile

Sunshine Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense148.9 K137.3 K153.4 K
Very volatile
Other Operating Expenses30.3 M28.9 M5.7 M
Slightly volatile
Total Operating Expenses13.8 M13.1 M3.3 M
Slightly volatile
Selling General Administrative10.6 M10.1 M2.7 M
Slightly volatile
Selling And Marketing Expenses771 K734.2 K436.8 K
Slightly volatile
Non Recurring106.5 K68.3 K144 K
Slightly volatile
Reconciled Depreciation132.1 K125.8 K28.4 K
Slightly volatile

Sunshine Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Other Non Cash Items3.7 M4.6 M3.2 M
Slightly volatile
Total Cash From Financing Activities3.4 M3.4 M3.7 M
Slightly volatile
End Period Cash Flow17.1 M16.3 M3.9 M
Slightly volatile
Begin Period Cash Flow22.9 M21.8 M3.2 M
Slightly volatile
Net Borrowings3.5 M3.3 M1.3 M
Slightly volatile
Depreciation156.6 K149.1 K34.2 K
Slightly volatile
Change To Netincome22.1 M21.1 M5.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.260.2742186.3 K
Slightly volatile
Days Sales Outstanding36.7338.6677285
Slightly volatile
Average Payables2.8 M2.7 M946.9 K
Slightly volatile
Stock Based Compensation To Revenue4.394.6229.5949
Slightly volatile
Capex To Depreciation5.025.28461.0577
Slightly volatile
Payables Turnover5.796.093187.884
Slightly volatile
Sales General And Administrative To Revenue0.40.419184
Slightly volatile
Research And Ddevelopement To Revenue0.07320.0772.3567
Slightly volatile
Capex To Revenue0.03110.0327146
Slightly volatile
Cash Per Share1.4 K1.3 K572
Slightly volatile
Days Payables Outstanding56.9159.9034412
Pretty Stable
Income Quality2.041.94740.5382
Slightly volatile
Intangibles To Total Assets0.05020.05280.4955
Slightly volatile
Current Ratio6.774.48325.6702
Pretty Stable
Receivables Turnover8.979.439419.1343
Slightly volatile
Graham NumberK3.8 K2.7 K
Slightly volatile
Capex Per Share71.0164.7841178
Slightly volatile
Average Receivables2.3 M2.2 M689.8 K
Slightly volatile
Revenue Per Share2.1 KK333
Slightly volatile
Debt To Assets0.140.12421.8509
Pretty Stable
Operating Cycle163172516
Slightly volatile
Days Of Payables Outstanding56.9159.9034412
Pretty Stable
Ebt Per Ebit0.820.85912.0289
Slightly volatile
Quick Ratio6.593.45035.4787
Pretty Stable
Net Income Per E B T0.771.09611.1853
Slightly volatile
Cash Ratio5.372.93464.4078
Very volatile
Days Of Sales Outstanding36.7338.6677285
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.231.08981.3204
Slightly volatile
Fixed Asset Turnover24.9823.79196.4366
Slightly volatile
Debt Ratio0.140.12421.8509
Pretty Stable
Price Sales Ratio0.260.2742186.3 K
Slightly volatile
Asset Turnover0.930.8810.2355
Slightly volatile

Sunshine Fundamental Market Drivers

Cash And Short Term Investments16.3 M

Sunshine Upcoming Events

2nd of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors utilize fundamental indicators, such as revenue or net income, to predict how Sunshine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue344.8 K192.1 K
Total Revenue24.1 M25.3 M
Cost Of Revenue15.8 M16.5 M
Stock Based Compensation To Revenue 4.62  4.39 
Sales General And Administrative To Revenue 0.42  0.40 
Research And Ddevelopement To Revenue 0.08  0.07 
Capex To Revenue 0.03  0.03 
Revenue Per ShareK2.1 K
Ebit Per Revenue(0.20)(0.21)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports:
Check out the analysis of Sunshine Biopharma Correlation against competitors.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(127.90)
Revenue Per Share
197.42
Quarterly Revenue Growth
0.416
Return On Assets
(0.11)
Return On Equity
(0.18)
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.